SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of PlasmodiumPNAS, 2014
A chemical rescue screen identifies a P.falcip. apicoplast inhibitor targeting MEP isoprenoid precursor biosynthesisAAC, 2014
Actionable Diagnosis of Neuroleptospirosis by Next-Generation SequencingNEJM, 2014
Ball Python Nidovirus: a Candidate Etiologic Agent for Severe Respiratory Disease in Python regiusmBio, 2014
Kruppel Mediates the Selective Rebalancing of Ion Channel ExpressionNeuron, 2014
The Kinase Regulator Mob1 Acts as a Patterning Protein for Stentor MorphogenesisPLoS Biology, 2014
Structural Characterization of the Glycoprotein GP2 Core Domain from the CAS Virus, a Novel ArenavirusJ. Mol. Bio., 2014
Despite recent impressive gains over the last decade in the fight against malaria, there exists an urgent need for new, fast acting medications to treat Plasmodium falciparum, the causative agent of the most deadly form of the disease. The need is especially acute given the emergence of artemesinin resistance in Asia. Here, we are please to announce a new candidate for a rapid-acting blood stage anti-malarial compound, SJ733. This compound has won Pre-Clinical Approval with the Malaria Medicines Venture. Its target, PfATP4, a sodium extrusion pump, is shown in a model above, with the compound docked in the presumptive sodium channel, where our data suggests that it impairs the function of the protein. The above image was rendered with UCSF Chimera by J.DeRisi, using a homology model and docked compound generated by J.Horst. Read the Paper Here!